SIGA Technologies Inc. has released a management presentation outlining recent company developments and financial performance. The presentation highlights ongoing label expansion efforts for TPOXX, SIGA's treatment for smallpox, and details its established supply chain and distribution model in the U.S. The company reported over $1 billion in procurement contracts across more than 30 countries, with approximately $590 million in TPOXX revenue and $370 million in pre-tax operating income between 2020 and 2024. SIGA continues to target regulatory submissions for new TPOXX indications, including post-exposure prophylaxis and a pediatric formulation. The company maintains a strong balance sheet, disciplined cash management, and no debt. You can access the full presentation through the link below.